These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21245074)

  • 1. Quantifying the economic burden of productivity loss in rheumatoid arthritis.
    Filipovic I; Walker D; Forster F; Curry AS
    Rheumatology (Oxford); 2011 Jun; 50(6):1083-90. PubMed ID: 21245074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
    Her M; Kavanaugh A
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment-A Systematic Literature Review.
    Batko B; Rolska-Wójcik P; Władysiuk M
    Int J Environ Res Public Health; 2019 Aug; 16(16):. PubMed ID: 31426543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States.
    Hone D; Cheng A; Watson C; Huang B; Bitman B; Huang XY; Gandra SR
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1564-72. PubMed ID: 23554320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
    Hu H; Luan L; Yang K; Li SC
    Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis.
    Birnbaum H; Pike C; Kaufman R; Cifaldi M
    J Occup Environ Med; 2009 Oct; 51(10):1167-76. PubMed ID: 19786900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study.
    Tanaka Y; Yamazaki K; Nakajima R; Komatsu S; Igarashi A; Tango T; Takeuchi T
    Mod Rheumatol; 2018 Jan; 28(1):39-47. PubMed ID: 28704126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect costs assessment and intangible costs description of rheumatoid arthritis patients with biological therapy in Morocco: ECORAM Study.
    Zarrik H; Hassani AC; Rkain H; Allali F; Bahiri R; Ahid S
    Int J Rheum Dis; 2024 Oct; 27(10):e15367. PubMed ID: 39373088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatoid arthritis and work: The impact of rheumatoid arthritis on absenteeism and presenteeism.
    Verstappen SM
    Best Pract Res Clin Rheumatol; 2015 Jun; 29(3):495-511. PubMed ID: 26612244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Productivity cost model of the treatment of rheumatoid arthritis with abatacept.
    Burton WN; Morrison A; Yuan Y; Li T; Marioni RE; Maclean R
    J Med Econ; 2008; 11(1):3-21. PubMed ID: 19450107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic burden of rheumatoid arthritis: beyond health care costs.
    Zhang W; Anis AH
    Clin Rheumatol; 2011 Mar; 30 Suppl 1():S25-32. PubMed ID: 21360103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a composite questionnaire, the valuation of lost productivity, to value productivity losses: application in rheumatoid arthritis.
    Zhang W; Bansback N; Boonen A; Severens JL; Anis AH
    Value Health; 2012 Jan; 15(1):46-54. PubMed ID: 22264971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.
    Hsieh PH; Wu O; Geue C; McIntosh E; McInnes IB; Siebert S
    Ann Rheum Dis; 2020 Jun; 79(6):771-777. PubMed ID: 32245893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of studies of productivity loss due to rheumatoid arthritis.
    Burton W; Morrison A; Maclean R; Ruderman E
    Occup Med (Lond); 2006 Jan; 56(1):18-27. PubMed ID: 16286432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis.
    Gwinnutt JM; Leggett S; Lunt M; Barton A; Hyrich KL; Walker-Bone K; Verstappen SMM;
    Rheumatology (Oxford); 2020 Oct; 59(10):2908-2919. PubMed ID: 32097471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.
    Puolakka K; Kautiainen H; Mottonen T; Hannonen P; Korpela M; Hakala M; Luukkainen R; Vuori K; Blåfield H; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(2):96-103. PubMed ID: 19274516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Medical and economic aspects of rheumatoid arthritis].
    Fautrel B; Gaujoux-Viala C
    Bull Acad Natl Med; 2012 Oct; 196(7):1295-305; discussion 1305-6. PubMed ID: 23815015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work.
    Li X; Gignac MA; Anis AH
    Med Care; 2006 Apr; 44(4):304-10. PubMed ID: 16565630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA project.
    Hallert E; Husberg M; Kalkan A; Skogh T; Bernfort L
    Scand J Rheumatol; 2014; 43(3):177-83. PubMed ID: 24354438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Productivity costs of rheumatoid arthritis in Germany. Cost composition and prediction of main cost components].
    Merkesdal S; Huelsemann JL; Mittendorf T; Zeh S; Zeidler H; Ruof J
    Z Rheumatol; 2006 Oct; 65(6):527-34. PubMed ID: 16534538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.